The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the ...

Endothelin-1 is a small vasoconstrictor peptide that was first identified in 1988. Here we review the evidence implicating ET-1 in tumorigenesis. In particular, we concentrate on the role of ET-1 ...

Participation of endothelin in salt-sensitive essential hypertension could be mediated by a deficit in its natriuretic actions, or by an exaggerated contribution to the control of vasoconstriction ...

CHICAGO, IL—Use of an investigational endothelin receptor antagonist in patients with resistant hypertension has a significant impact on both automated office and 24-ambulatory blood pressure when ...

TRYVIO (aprocitentan) is an endothelin receptor antagonist that inhibits the binding of endothelin (ET)-1 to ETA and ETBreceptors.1,2The effects of ET-1 bear many similarities with the ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

According to Briyal and her mentor Anil Gulati, PhD, this is the first report to indicate that selective stimulation of the endothelin B receptors by IV injection of IRL-1620 improves memory, reduces ...

PER-001 (Perfuse Therapeutics), an endothelin antagonist, was delivered at low and high doses and compared with control, showing structure improvements in macular ischemia, leakage and microaneurysms.

Endothelin antagonists fail in ENCOR chronic heart failure study Lisa Nainggolan March 21, 2001 0 Wed, 21 Mar 2001 18:42:00 ...

SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2 ...

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, ...

Swiss pharma company Idorsia announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has ...